CASE REPORT

Renal Involvement as Rare Acute Tubulointerstitial Nephritis in a Patient with Eosinophilic Disorder Treated with Early Add-on Administration of Mepolizumab

Yuto Hayama, Tomyo Fuminori, Masaki Ueno, Shinichiro Asakawa, Shigeyuki Arai, Osamu Yamazaki, Yoshifuru Tamura, Makoto Mochizuki, Ryuji Ohashi, Shigeru Shibata and Yoshihide Fujigaki

Abstract:
A 39-year-old man presented with peripheral eosinophilia, pulmonary eosinophilic infiltrate, and renal failure due to acute tubulointerstitial nephritis (TIN). He had experienced childhood asthma and was negative for anti-neutrophil cytoplasmic antibody (ANCA). He was tentatively diagnosed with ANCA-negative eosinophilic granulomatous polyangiitis (EGPA) or idiopathic hypereosinophilic syndrome (HES). Renal involvement of isolated TIN with eosinophil infiltration is rare in EGPA and HES and does not seem to have a good prognosis in the literature. However, his condition improved well with corticosteroids and mepolizumab. The revised classification of EGPA based on the etiology should dictate the proper treatment in suspected EGPA patients with nonsystemic vasculitis.

Key words: anti-neutrophil cytoplasmic antibody, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, mepolizumab, tubulointerstitial nephritis

(Intern Med Advance Publication) (DOI: 10.2169/internalmedicine.7490-21)

Introduction

The diagnosis of idiopathic hypereosinophilic syndrome (HES) is based on Chusid’s criteria, which are as follows: marked eosinophilia (absolute eosinophil count >1,500/μL), chronic course (>6 months), the exclusion of other evident etiologies for eosinophilia and signs or symptoms of eosinophil-mediated tissue injury (1). However, idiopathic HES and eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome (CSS), have a shared feature regarding the clinical phenotypes of hypereosinophilia and organ injuries. EGPA is a member of the anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis family, although ANCA positivity is found in 30% to 40% of EGPA patients (2). The diagnosis of EGPA is usually easy when the patient has ANCA positivity with typical clinical features and/or histological signs of vasculitis (3). However, in patients with a history of asthma and sinusitis, distinguishing between ANCA-negative EGPA and idiopathic HES is difficult due to the significant overlap in the clinical presentation and biomarker profiles (4).

We herein report an ANCA-negative patient with peripheral eosinophilia, pulmonary eosinophilic infiltrate and isolated tubulointerstitial nephritis (TIN) for which corticosteroid and mepolizumab were effective. The patient was tentatively diagnosed with idiopathic HES or ANCA-negative EGPA. Renal involvement as isolated TIN with eosinophil infiltration is rare in eosinophilic disorders. We performed a review of the literature in acute renal insufficiency due to isolated TIN in EGPA and idiopathic HES to examine their characteristics.
Case Report

A 39-year-old man presented with headache and a fever 2 days prior to his admission and was treated with acetaminophen by a local physician 1 day prior. His symptoms worsened, and he appeared at the emergency unit in our hospital. He also complained of slight productive cough and mild diarrhea. Chest computed tomography (CT) revealed peripheral dominant multiple ground-glass opacities with consolidations in both lung fields (Fig. 1A, B) and bilateral slight enlargement of the kidneys. He was admitted to our hospital with peripheral hyper eosinophilia, pulmonary infiltrate and renal insufficiency. His medical history included childhood asthma at 5 years of age and appendectomy at 11 years of age. His asthma had been almost inactive except for slight symptoms when he had a cold. He was a current smoker. He had no food or drug allergies and used no over-the-counter drugs, medical herbal supplements or dietary supplements, except for acetaminophen 1 day before admission. He had no history of parasitic diseases and did not customarily eat raw or undercooked meat.

A physical examination on admission revealed the following: body height, 171.5 cm; body weight, 66.8 kg; temperature, 41.0°C; blood pressure, 141/86 mmHg; heart rate, 102 beats/min; and oxygen saturation, 95%. He did not show cardiac murmur or abnormal breath sounds. He had no abnormal findings upon examination of the tonsils, skin, peripheral lymph nodes, joints and neuromuscular system. A urinalysis revealed the following results: 1+ occult blood; 2+ protein; 20-29 red blood cells/high-power field and the presence of granular and waxy casts. Urinary chemistry revealed the following findings: protein, 0.30 g/g creatinine; N-acetyl-β-D-glucosaminidase, 29.2 U/L; β 2-microglobulin, 3,042 μg/L; and alpha 1-microglobulin, 80.0 mg/L, indicating tubulointerstitial injuries. A blood analysis revealed the following findings: hemoglobin, 14.4 g/dL; WBC count, 15,400/μL with eosinophil count, 2,156/μL; platelet count, 170,000/μL; albumin, 3.2 g/dL; blood urea nitrogen, 8.9 mg/dL; creatinine, 1.21 mg/dL; Na, 139 mEq/L and K, 3.3 mEq/L. The immunological findings were as follows: C-reactive protein, 12.85 mg/dL; IgG 609 mg/dL, IgA 153 mg/dL, IgM 62 mg/dL, IgE 1,803 IU/mL (normal <100); hepatitis B and C serology, normal; human immunodeficiency virus antibody test, negative; anti-nuclear antibody, negative; anti-DNA antibody, negative; myeloperoxidase (MPO)- and proteinase 3 (PR3)-ANCAs, negative; and anti-glomerular basement membrane antibody; negative. His results for allergic tests were negative. A cellular analysis of the bronchoalveolar lavage fluid revealed 30% eosinophils, indicating pulmonary eosinophilic infiltrate. An examination of the stool for parasites was negative. His diarrhea disappeared before the treatment. His electrocardiogram showed nonspecific T wave abnormalities. An echocardiographic examination detected a normal left ventricular function and no pericardial effusion or thrombus.

Steroid pulse therapy for 3 days with subsequent oral prednisolone at 50 mg/day was started for pulmonary eosinophilic infiltrate, and a deteriorated renal function with 6.04 mg/dL serum creatinine was noted on the 4th day after admission. Hemodialysis was introduced due to oliguria on the 5th day. Since the urinary volume was increased and the renal function began to improve, hemodialysis was not further required.

A kidney biopsy performed 8 days after the treatment revealed no glomerular lesions, including crescent formation, among 39 obtained glomeruli. There were many focal inflammatory cell infiltrations with a mild degree of tubulitis but no granulomas or peritubular capillaritis with neutrophil infiltration (Fig. 2A). Some inflammatory cell infiltrations in the tubulointerstitial areas included a moderate number of eosinophils (Fig. 2B). Edema and fibrosis were found in approximately 20% of the cortical areas. No vasculitis was found in any level of the arteries. An immunofluorescence study was negative for IgG, IgA, IgM, C1q and C3. These findings confirmed isolated acute TIN and suggested a re-
Figure 2. Light microscopic findings of a kidney biopsy. A: Focal interstitial inflammatory cell infiltrates are found. Periodic acid-Schiff staining. Original magnification ×200. B: Interstitial inflammatory cell infiltrates with a moderate number of eosinophilic cells (arrows). Hematoxylin and Eosin staining. Original magnification ×400.

Figure 3. Clinical course. mP and arrowhead: steroid pulse therapy (1,000 mg methylprednisolone, daily boluses given for 3 days).

solving phase of eosinophilic TIN after corticosteroid therapy. Although isolated eosinophilic TIN is rare, he was tentatively diagnosed with suspected EGPA or idiopathic HES. Just after steroid pulse therapy, his blood eosinophil count became 0/μL (Fig. 3). However, the percentage of eosinophils in the blood was more than 10% again, and 300 mg of the anti-interleukin-5 (IL-5) monoclonal antibody mepolizumab subcutaneously every 4 weeks was added to oral prednisolone at 50 mg/day 9 days after steroid therapy to achieve remission, reduce the dose of prednisolone and prevent recurrence. His blood eosinophil proportion soon became 1% to 3% and was almost 0/μL at 2 months after the treatment (Fig. 3). Urinary N-acetyl-β-D-glucosaminidase, β2-microglobulin and alpha 1-microglobulin levels were normalized, and serum creatinine levels were decreased to 0.79 mg/dL 26 days after the treatment. Computed tomography revealed no ground-glass opacities or consolidations in either the lungs or the normal-sized kidneys at 24 days after the treatment. Prednisolone was reduced to 10 mg/day at 14 weeks after the treatment and tapered off. He remained well while receiving only mepolizumab at 300 mg every 4 weeks, and his blood eosinophil count was 114/μL, IgE was 207 IU/mL, and serum creatinine was 0.80 mg/dL at 17 months after the treatment.
Discussion

We herein report an ANCA-negative patient with childhood asthma, peripheral eosinophilia, pulmonary eosinophilic infiltrate and acute renal insufficiency due to possible eosinophilic TIN who was successfully treated with corticosteroids and mepolizumab.

Our patient took a therapeutic dose of acetaminophen one day before admission. Acetaminophen-induced eosinophilic pneumonia has been reported in a small number of cases (5), and acute tubulointerstitial nephritis with eosinophil infiltrate due to acetaminophen was also reported in a few cases (6). However, no cases of drug-induced HES involving both the lung and kidney without dermatological involvement have been reported. Drug-induced HES may be caused by a delayed hypersensitivity reaction. When patients have previously been sensitized with acetaminophen, a delayed hypersensitivity reaction may occur soon after the repeated use of acetaminophen. However, it is unlikely that the severe lung and kidney involvement seen in our patient would have been induced only one day after acetaminophen use. Furthermore, the worsened renal function in our patient even after the discontinuation of acetaminophen did not support acetaminophen-induced HES.

EGPA is “Eosinophil-rich and necrotizing granulomatous inflammation often involving the respiratory tract, and necrotizing vasculitis predominantly affecting small to medium vessels, and associated with asthma and eosinophilia” (7). ANCA is more frequent when glomerulonephritis is present than in its absence (7). The diagnostic criteria for EGPA established by Lanham et al. include systemic vasculitis involving two or more extrapulmonary organs (8). Our patient did not show systemic vasculitic manifestations, so he did not meet Lanham’s criteria. A history of asthma is a key criterion for EGPA based on Lanham’s criteria (8) and the American College of Rheumatology 1990 criteria (3). Our patient had childhood asthma, but his asthma was not late-onset or newly worsened, as is commonly seen in EGPA (9). Therefore, the diagnosis of EGPA was indeterminate in our patient.

In contrast, HES shares many features with EGPA. HES comprises a group of diseases that are characterized by prolonged peripheral eosinophilia and organ damage in the absence of secondary causes for eosinophilia. HES is classified as myeloproliferative, lymphoproliferative, overlap, idiopathic and associated variants of HES. Idiopathic HES is now restricted to patients with HES of undetermined etiology (1, 10). Although the chronic course of eosinophilia was not determined and precise examinations to classify HES were not performed in our patient, if he did not have EGPA, he seems to have had idiopathic HES.

According to a recent genome-wide association study with stratification by ANCA revealed that EGPA comprises two genetically and clinically distinct syndromes (11). MPO-ANCA-positive EGPA is an eosinophilic autoimmune disease sharing certain clinical features and an HLA-DQ association with ANCA-associated vasculitis, while ANCA-negative EGPA may instead have a mucosal/barrier dysfunction origin, sharing features with asthma (11). Interestingly, it has been suggested that patients who present with asthma, an eosinophil count above 1,500/μL and systemic manifestations (other than asthma, pulmonary or ear, nose and throat involvement) directly attributable to EGPA but no vasculitis or ANCA may be considered to suffer from idiopathic HES (12, 13). Even if the history of asthma in our patient is accepted as a criterion for EGPA, our patient might be considered to have had idiopathic HES.

Although ANCA-positive EGPA sometimes shows pauci-immune necrotizing glomerulonephritis with TIN with eosinophilic infiltration (7), patients with CSS/EGPA presenting with acute renal insufficiency due to biopsy-proven TIN in the English-language literature are rare. Recently, a multicentric retrospective study by the GERM®TOP and the European Respiratory Society Taskforce on EGPA reported no TIN in 157 EGPA patients based on the presence or absence of definitive vasculitis features and/or ANCA status (13). A more recent multicentric retrospective study of 63 biopsy-proven cases with EGPA (53 ANCA-positive cases and 10 ANCA-negative cases) revealed that isolated TIN was found in 5 (9%) ANCA-positive cases and 1 (10%) ANCA-negative case, suggesting that isolated TIN can occur in both ANCA-positive and ANCA-negative EGPA patients (14).

To our knowledge, renal insufficiency due to isolated TIN has been reported in only three CCS/EGPA cases, with some details included (15-17) (Table). In contrast, HES most commonly involves the heart, lungs, nervous system and skin (18). While renal involvement is rare in HES, renal manifestations include eosinophilic TIN, various types of glomerulopathies, thrombotic microangiopathy and electrolyte disturbances (18, 19). Three cases with isolated eosinophilic TIN in idiopathic HES (20-22) were found (Table). Based on the limited data of CSS/EGPA and idiopathic HES with isolated TIN (Table), the age of patients ranged from 25 to 77 years old. Most cases show pulmonary involvement, although whether or not pulmonary involvement is caused by eosinophil infiltration is unclear. High IgE levels were found in most cases. Urinary abnormalities tended to be mild, similar to those associated with other causes of TIN. Two of the patients required temporary dialysis therapy, but one had chronic kidney disease due to diabetic nephropathy. At least half of the cases had irreversible severe renal damage. The characteristics were compatible with those in our patient except for the poor renal prognosis. The mechanisms underlying eosinophilic TIN in eosinophilic disorders are suspected to involve eosinophil cytotoxicity and the mass effect due to eosinophil infiltrates, which are also implicated in other damaged organs. However, the precise reason why isolated eosinophilic TIN has rarely been associated with eosinophilic disorders is unclear when compared with eosinophilic infiltration in other organs.
monoclonal antibody against IL-5 that reduces blood eosinophil
counts, has been used to treat severe asthma and eosino-
philic disorders, including EGPA and idiopathic HES (25).
However, mepolizumab was effective in achieving protocol-
controlled phase III study demonstrated that treatment with
mepolizumab was effective in 72% of patients with HES
and was associated with a 50% reduction in the proportion of
patients who experienced 1 or more flares during the 32-
week treatment period compared with treatment with placebo (27).

Our patient with EGPA or idiopathic HES had severe pul-
monary involvement and severe renal involvement requiring
hemodialysis and started off with high-dose corticosteroids
treatment. His blood eosinophil count became 0/μL just after
steroid pulse therapy (Fig. 3). However, the percentage of
eosinophils in the blood increased to over 10% again while
on prednisolone at 50 mg/day. Therefore, we considered re-
introduction of protocol-defined remission in approximately half of EGPA patients
but not in the entire trial cohort in MIRRA, a phase III
trial (26). One potential reason for this is that EGPA is a
heterogeneous disease with some manifestations being
oneosinophil-driven (26). For HES, a randomized, placebo-
controlled phase III trial demonstrated that treatment with
mepolizumab was effective in 72% of patients with HES
and was associated with a 50% reduction in the proportion of
patients who experienced 1 or more flares during the 32-
week treatment period compared with treatment with placebo (27).

Our patient with EGPA or idiopathic HES had severe pul-
monary involvement and severe renal involvement requiring
hemodialysis and started off with high-dose corticosteroids
treatment. His blood eosinophil count became 0/μL just after
steroid pulse therapy (Fig. 3). However, the percentage of
eosinophils in the blood increased to over 10% again while
on prednisolone at 50 mg/day. Therefore, we considered re-
introduction of protocol-defined remission in approximately half of EGPA patients
but not in the entire trial cohort in MIRRA, a phase III
trial (26). One potential reason for this is that EGPA is a
heterogeneous disease with some manifestations being
oneosinophil-driven (26). For HES, a randomized, placebo-
controlled phase III study demonstrated that treatment with
mepolizumab was effective in 72% of patients with HES
and was associated with a 50% reduction in the proportion of
patients who experienced 1 or more flares during the 32-
week treatment period compared with treatment with placebo (27).

Our patient with EGPA or idiopathic HES had severe pul-
monary involvement and severe renal involvement requiring
hemodialysis and started off with high-dose corticosteroids
treatment. His blood eosinophil count became 0/μL just after
steroid pulse therapy (Fig. 3). However, the percentage of
eosinophils in the blood increased to over 10% again while
on prednisolone at 50 mg/day. Therefore, we considered re-
introduction of protocol-defined remission in approximately half of EGPA patients
but not in the entire trial cohort in MIRRA, a phase III
trial (26). One potential reason for this is that EGPA is a
heterogeneous disease with some manifestations being
oneosinophil-driven (26). For HES, a randomized, placebo-
controlled phase III study demonstrated that treatment with
mepolizumab was effective in 72% of patients with HES
and was associated with a 50% reduction in the proportion of
patients who experienced 1 or more flares during the 32-
week treatment period compared with treatment with placebo (27).

Our patient with EGPA or idiopathic HES had severe pul-
monary involvement and severe renal involvement requiring
hemodialysis and started off with high-dose corticosteroids
treatment. His blood eosinophil count became 0/μL just after
steroid pulse therapy (Fig. 3). However, the percentage of
eosinophils in the blood increased to over 10% again while
on prednisolone at 50 mg/day. Therefore, we considered re-
introduction of protocol-defined remission in approximately half of EGPA patients
but not in the entire trial cohort in MIRRA, a phase III
trial (26). One potential reason for this is that EGPA is a
heterogeneous disease with some manifestations being
oneosinophil-driven (26). For HES, a randomized, placebo-
controlled phase III study demonstrated that treatment with
mepolizumab was effective in 72% of patients with HES
and was associated with a 50% reduction in the proportion of
patients who experienced 1 or more flares during the 32-
week treatment period compared with treatment with placebo (27).

Our patient with EGPA or idiopathic HES had severe pul-
monary involvement and severe renal involvement requiring
hemodialysis and started off with high-dose corticosteroids
treatment. His blood eosinophil count became 0/μL just after
steroid pulse therapy (Fig. 3). However, the percentage of
eosinophils in the blood increased to over 10% again while
on prednisolone at 50 mg/day. Therefore, we considered re-
introduction of protocol-defined remission in approximately half of EGPA patients
but not in the entire trial cohort in MIRRA, a phase III
trial (26). One potential reason for this is that EGPA is a
heterogeneous disease with some manifestations being
oneosinophil-driven (26). For HES, a randomized, placebo-
controlled phase III study demonstrated that treatment with
mepolizumab was effective in 72% of patients with HES
and was associated with a 50% reduction in the proportion of
patients who experienced 1 or more flares during the 32-
week treatment period compared with treatment with placebo (27).

Our patient with EGPA or idiopathic HES had severe pul-
monary involvement and severe renal involvement requiring
hemodialysis and started off with high-dose corticosteroids
treatment. His blood eosinophil count became 0/μL just after
steroid pulse therapy (Fig. 3). However, the percentage of
eosinophils in the blood increased to over 10% again while
on prednisolone at 50 mg/day. Therefore, we considered re-
introduction of protocol-defined remission in approximately half of EGPA patients
but not in the entire trial cohort in MIRRA, a phase III
trial (26). One potential reason for this is that EGPA is a
heterogeneous disease with some manifestations being
oneosinophil-driven (26). For HES, a randomized, placebo-
controlled phase III study demonstrated that treatment with
mepolizumab was effective in 72% of patients with HES
and was associated with a 50% reduction in the proportion of
patients who experienced 1 or more flares during the 32-
week treatment period compared with treatment with placebo (27).

Our patient with EGPA or idiopathic HES had severe pul-
monary involvement and severe renal involvement requiring
hemodialysis and started off with high-dose corticosteroids
treatment. His blood eosinophil count became 0/μL just after
steroid pulse therapy (Fig. 3). However, the percentage of
eosinophils in the blood increased to over 10% again while
on prednisolone at 50 mg/day. Therefore, we considered re-
introduction of protocol-defined remission in approximately half of EGPA patients
but not in the entire trial cohort in MIRRA, a phase III
trial (26). One potential reason for this is that EGPA is a
heterogeneous disease with some manifestations being
oneosinophil-driven (26). For HES, a randomized, placebo-
controlled phase III study demonstrated that treatment with
mepolizumab was effective in 72% of patients with HES
and was associated with a 50% reduction in the proportion of
patients who experienced 1 or more flares during the 32-
week treatment period compared with treatment with placebo (27).
mepolizumab since we expected a rapid remission with a maintenance of such remission without any significant adverse effects. Our patient had a very good response to treatment with mepolizumab as an add-on therapy to corticosteroid treatment for EGPA (26, 27), probably because the disease was eosinophil-driven. The clinical benefits of treatment with mepolizumab in our patient may include early recovery of symptoms and organ damage, prevention of recurrence and the ability to decrease the prednisolone dose at an early point. Proper and prompt treatment based on the etiology of eosinophilic disorders is necessary before irreversible organ damage occurs.

In summary, we presented an ANCA-negative, nonvasculitic case with childhood asthma, eosinophilia, pulmonary eosinophilic infiltrate and rare isolated TIN. Though our case was difficult to definitively diagnose with EGPA or idiopathic HES, he was successfully treated with corticosteroids and mepolizumab. Regarding the choice of treatment strategy, a revised classification of EGPA based on the etiology may be required, especially in ANCA-negative, nonsystemic vasculitic EGPA patients at the present classification.

The authors state that they have no Conflict of Interest (COI).

References

1. Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis 2: 37, 2007.
2. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52: 2926-2935, 2005.
3. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: 1094-1100, 1990.
4. Khoury P, Zagal Z, Talar-Williams C, et al. Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy 67: 1149-1156, 2012.
5. Saint-Pierre MD, Moran-Mendoza O. Acetaminophen Use: An Unusual Cause of Drug-Induced Pulmonary Eosinophilia. Can Respir J 2016: 4287270, 2016.
6. Inoue D, Utsui R, Nitta K, Koike M. A case of acetaminophen-induced acute tubulointerstitial nephritis in adult. CEN Case Rep 6: 185-188, 2017.
7. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65: 1-11, 2013.
8. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63: 65-68, 1984.
9. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 115: 284-290, 2003.
10. Cogan E, Roufosse F. Clinical management of the hypereosinophilic syndromes. Expert Rev Hematol 5: 275-289, 2012.
11. Lyons PA, Peters JE, Alberici F, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun 10: 5120, 2019.
12. Lefèvre G, Ackermann F, Kahn JE. Hypereosinophilia with asthma and systemic (non-vasculitic) manifestations: Eosinophilic granulomatosis with polyangiitis or hypereosinophilic syndrome? Autoimmun Rev 16: 208-209, 2017.
13. Cottin V, Bel E, Bottero P, et al.; Groupe d’Études et de Recherche sur les Maladies Orphelines Pulmonaires (GERM’O’P). Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d’Études et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Autoimmun Rev 16: 1-9, 2017.
14. Durel CA, Sinico RA, Teixeira V, et al.; French Vasculitis Study Group (FVSG). Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. Rheumatology (Oxford) 60: 359-365, 2021.
15. Davenport A, McDicken I, Goldsmith HJ. Reversible acute renal failure due to Churg-Strauss syndrome. Postgrad Med J 64: 713-715, 1988.
16. Sinico RA, Di Toma L, Maggiore U, et al. Renal involvement in Churg-Strauss syndrome. Ann J Kidney Dis 47: 770-779, 2006.
17. Chen Y, Ding Y, Liu Z, Zhang H, Liu Z, Hu W. Long-term outcomes in antineutrophil cytoplasmic autoantibody-positive eosinophilic granulomatosis with polyangiitis patients with renal involvement: a retrospective study of 14 Chinese patients. BMC Nephrol 17: 101, 2016.
18. Spry CJ. The hypereosinophilic syndrome: clinical features, laboratory findings and treatment. Allergy 37: 539-551, 1982.
19. Shihwaro N, Langlois AL, Gueutin V, Izzedine H. Renal involvement in idiopathic hypereosinophilic syndrome. Clin Kidney J 6: 272-276, 2013.
20. Motellón JL, Bernis C, García-Sánchez A, Gruss E, Traver JA. Renal involvement in the hypereosinophilic syndrome. Nephrol Dial Transplant 10: 401-403, 1995.
21. Bulucu F, Can C, Inal V, Baykal Y, Erikg D, S. Renal involvement in a patient with idiopathic hypereosinophilic syndrome. Clin Nephrol 57: 171-173, 2002.
22. Navarro I, Torras J, Gomà M, Cruzado JM, Grinyó JM. Renal involvement as the first manifestation of hypereosinophilic syndrome: a case report. NDT Plus 3: 361-361, 2009.
23. Raffray L, Guillermin L. Updates for the treatment of EGPA. Presse Med 49: 104036, 2020.
24. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 94: 1149-1167, 2019.
25. Caminati M, Menzella F, Guidolin L, Senna G. Targeting eosinophils: severe asthma and beyond. Drugs Context 8: 212587, 2019.
26. Wechsler ME, Akuthota P, Jayne D, et al.; EGPA Mepolizumab Study Team. Mepolizumab or Placebo for Eosinophil Granulomatosis with Polyangiitis. N Engl J Med 376: 1921-1932, 2017.
27. Roufosse F, Kahn JE, Rothenberg ME, et al.; HES Mepolizumab study group. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol 146: 1397-1405, 2020.
28. Koike H, Akiyama K, Saito T, Sobe G; Research Group for IVIG for EGPA/CSS in Japan. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial. J Neurol 262: 752-759, 2015.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
